Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GJA1 | P17302 | 1/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727956 | 1.00 | PTPN1 (0.56) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL16788268 | 1.00 | PTPN1 (0.56) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL18872330 | 1.00 | PTPN1 (0.56) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL27345634 | 1.00 | PTPN1 (0.56) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL167126 | 1.00 | PTPN1 (0.56) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL7688096 | 0.98 | PTPN1 (0.57) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL20097839 | 0.98 | PTPN1 (0.57) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL11288598 | 0.98 | PTPN1 (0.57) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL21012995 | 0.95 | PTPN1 (0.57) | PTPN1SYNJ2MEN1KMT2AGJA1 | |
| SCHEMBL19840460 | 0.86 | PTPN1 (0.56) | PTPN1SYNJ2MEN1KMT2AGJA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004222-B2 | Small molecule ice recrystallization inhibitors and methods of use thereof | THE UNIVERSITY OF OTTAWA (CA) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004222-B2 | Small molecule ice recrystallization inhibitors and methods of use thereof | MCL1, IDH3B, IDH3A | PTPN1 2063/4885SYNJ2 3552/4885MEN1 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.